Hemostasis

Baxter Launches PERCLOT Absorbable Hemostatic Powder

Retrieved on: 
Monday, July 24, 2023
Surgery, Health, Medical Supplies, Surgeon, Bleeding, Baxter, Thrombin, Multimedia, Baxter International, Information International, Inc., Fibrinogen, Hospital, Hemostasis, Patient, Non-Euclidean geometry, NYSE

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.1

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230724490511/en/
    “PERCLOT is a strong complement to Baxter’s leading hemostat portfolio,” said Steve Wallace, president, Advanced Surgery at Baxter.
  • PERCLOT further enhances clinicians’ ability to optimize patient care by addressing a broader range of intraoperative bleeding.
  • Baxter has successfully continued to expand the global commercial presence of PERCLOT since acquiring the product in July 2021 .

Medcura Inc. Appoints Jacob Rodman to Board of Directors, Preparing for LifeGel™ Flowable Hemostat Launch and Expanding Market Reach

Retrieved on: 
Tuesday, July 18, 2023
Powder, Walmart, American Education Society, CVS, Rapids, Paralysis, Hospital, Hemostasis, Swelling, Neurosurgery, FDA, Trauma, Walgreens, Amazon, Nerve

RIVERDALE, Md., July 18, 2023 /PRNewswire/ -- Medcura Inc., proudly announces the appointment of Jacob Rodman to its Board of Directors.

Key Points: 
  • RIVERDALE, Md., July 18, 2023 /PRNewswire/ -- Medcura Inc., proudly announces the appointment of Jacob Rodman to its Board of Directors.
  • Jacob is the CEO of Raleigh Neurosurgical Clinic, Inc., and the president-elect of Nerves (Neurosurgery Executives Resource Value & Education Society).
  • "We are delighted to welcome Jacob Rodman to our Board of Directors.
  • Jacob Rodman expressed his regard for joining Medcura's Board of Directors, stating, "It is a privilege to serve on Medcura's Board of Directors.

Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab

Retrieved on: 
Thursday, June 8, 2023
Medical device, CAT, VTE, Atrial fibrillation, Factor XI, Prevalence, Stroke, Medication, Clinical trial, Cancer, Xi, ASTER, Anthos, Thrombosis, Anticoagulant, Coronary thrombosis, Hemostasis, DSM-IV codes, Patient, PMDA, National Medical Products Administration, AF, FDA, Therapy, Death, NMPA, Pharmaceutical industry

CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced two important regulatory milestones in China and Japan for clinical trials of the company’s investigational agent, abelacimab. Abelacimab is a novel, highly selective, dual-acting, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI and Factor XIa inhibition.

Key Points: 
  • Abelacimab is a novel, highly selective, dual-acting, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI and Factor XIa inhibition.
  • In China, the National Medical Products Administration (NMPA) has granted approval for abelacimab to be studied in the ASTER and MAGNOLIA Phase 3 clinical trials which form the Cancer Associated Thrombosis clinical trial program for Anthos.
  • Additionally, the Company received approval to initiate the Phase 3 LILAC-TIMI 76 trial investigating abelacimab in atrial fibrillation (AF) patients deemed unsuitable for current anticoagulants.
  • Abelacimab is an investigational agent that has not been approved for any indication in any country.

World Hematology and Coagulation Market Research Report 2023: A Nearly $10 Billion-Dollar Market - Demand for Decentralized Testing, New Technologies and Aging Populations Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 6, 2023
Health, Biotechnology, Platelet, Hematocrit, Stroke, Decentralization, Segment, Enzyme, Ageing, Artery, Cell, Fibrinolysis, Government, Literature, Protein, Bone marrow, PTT, Hemostasis, CBC, Laboratory, Country Markets, Blood, Anemia, IVD, Reticulocyte, Automation, Cryptocurrency, Microscope, Birth control, Renewable energy, Coagulation, Hematology

There is a nearly $10 billion-dollar market for hematology and coagulation IVD testing.

Key Points: 
  • There is a nearly $10 billion-dollar market for hematology and coagulation IVD testing.
  • Increasingly growth is driven by new technologies, the aging population, and the demand for decentralized testing.
  • The basis of hematology testing is the complete blood count (CBC) that provides information on blood components: hemoglobin, hematocrit, red blood cells, white blood cells, reticulocytes, and platelets.
  • The CBC is run as part of the normal work up in an annual health exam and for every inpatient.

CHOP's Hemostasis and Thrombosis Center Celebrates 50th Anniversary

Retrieved on: 
Wednesday, June 7, 2023
Ruth M. Rothstein CORE Center, Bleeding, Vein, CHOP, HIV, Hematology, Mother, Disability, Emicizumab, Hockey, Therapy, Novel, Not, Haemophilia, IX, Philadelphia, Coagulopathy, DSM-IV codes, Bleeding diathesis, Child, HTC, CDC, Pain, Social, Disorder, AIDS, MD, Patient, Nursing, Division, Maternal and Child Health Bureau, Thrombosis, Diagnosis, Hospital, World Blood Donor Day, Caregiver, FDA, Hemostasis, Football, National Intrepid Center of Excellence, Disease, Children's Hospital of Philadelphia, Birth control, Pharmaceutical industry

PHILADELPHIA, June 7, 2023 /PRNewswire/ -- The Hemostasis and Thrombosis Center (HTC) at Children's Hospital of Philadelphia (CHOP) is proudly celebrating 50 years of providing comprehensive care to children and adolescents with hemophilia and other inherited bleeding or clotting disorders. The Center was founded in 1973 and was one of the first HTCs established in the country and is considered a Center of Excellence for the diagnosis, treatment and prevention of bleeding and clotting disorders, serving as a national resource for other institutions.

Key Points: 
  • PHILADELPHIA, June 7, 2023 /PRNewswire/ -- The Hemostasis and Thrombosis Center (HTC) at Children's Hospital of Philadelphia (CHOP) is proudly celebrating 50 years of providing comprehensive care to children and adolescents with hemophilia and other inherited bleeding or clotting disorders.
  • "What started at CHOP as caring for 48 patients a year with hemophilia has grown into providing care for over 1,000 children with all types of bleeding and clotting disorders at our Center," says Leslie Raffini, MD, Director of the Hemostasis and Thrombosis Center at Children's Hospital of Philadelphia.
  • Hemophilia is an X-linked inherited bleeding disorder that is caused by a clotting factor deficiency that can cause frequent, painful joint bleeds and disability.
  • During this time, donated blood was the only treatment available for hemophilia patients, which led to many of them becoming infected with HIV.

Distinguished Cardiac Surgeon Dr. Abbas Ardehali Joins Medcura's Board of Directors

Retrieved on: 
Thursday, June 1, 2023
David Geffen School of Medicine at UCLA, Surgeon, Bleeding, Powder, Infection, Spine, Medicine, Paralysis, Hemostasis, Pet, Abbas Ardehali, UCLA, FDA, Nerve, Trauma, Dentistry

RIVERDALE, Md., June 1, 2023 /PRNewswire/ -- Medcura Inc. welcomes Dr. Abbas Ardehali to its Board of Directors.

Key Points: 
  • RIVERDALE, Md., June 1, 2023 /PRNewswire/ -- Medcura Inc. welcomes Dr. Abbas Ardehali to its Board of Directors.
  • Dr. Ardehali is a professor of surgery and medicine in the division of cardiothoracic surgery at the David Geffen School of Medicine at UCLA.
  • Dr. Ardehali also serves as director of the UCLA Heart and Lung Transplant program.
  • "Dr. Ardehali is a fantastic addition to our board of directors.

Accomplished Scientist and Biosurgery Industry Veteran Dr. Neil Winterbottom Joins Medcura's Leadership Team

Retrieved on: 
Wednesday, May 24, 2023
Partnership, University, Biochemistry, Powder, Spine, Research, Paralysis, Publication, Hemostasis, Risk, FDA, SVP, Nerve, Trauma, Medical device, Pharmaceutical industry

RIVERDALE, Md., May 24, 2023 /PRNewswire/ -- Medcura, Inc. has added Dr. Neil Winterbottom to its leadership team to accelerate the spine indication approval and commercialization of LifeGel™, Medcura's flagship surgical hemostat.

Key Points: 
  • Medcura, Inc. is delighted to welcome biochemist Dr. Neil Winterbottom as its new SVP of Product Development & Manufacturing Operations.
  • Dr. Winterbottom has over 20 years of experience leading research and development teams from concept to commercialization, including teams working on sealants and hemostatic agents.
  • Dr. Winterbottom holds a doctorate degree in oral biology and biochemistry from the University of Alberta.
  • Neil has a proven track record of success in launching new hemostatic agents and surgical sealant products to the market.

WERFEN SIGNS LONG-TERM, EXCLUSIVE WORLDWIDE DISTRIBUTOR AGREEMENT WITH THERMO FISHER SCIENTIFIC FOR HEMOSTASIS TESTING WORKCELL

Retrieved on: 
Thursday, May 4, 2023
Partnership, Workflow, Thermo Fisher Scientific, STAT, Laboratory, ACL, Safety, Medical device, Fine chemical, Werfen, Hemostasis

BEDFORD, Mass., May 4, 2023 /PRNewswire/ -- Werfen today announced they have signed a new long-term, exclusive partnership agreement with Thermo Fisher Scientific, for worldwide distribution of TCAutomation laboratory automation system, in the specialized field of Hemostasis Diagnostics. Following their previous exclusive agreement, signed in 2015, this allows Werfen to continue offering HemoCell Specialized Lab Automation, with the largest installed base of Hemostasis automation workcells globally.

Key Points: 
  • BEDFORD, Mass., May 4, 2023 /PRNewswire/ -- Werfen today announced they have signed a new long-term, exclusive partnership agreement with Thermo Fisher Scientific, for worldwide distribution of TCAutomation laboratory automation system, in the specialized field of Hemostasis Diagnostics.
  • Following their previous exclusive agreement, signed in 2015, this allows Werfen to continue offering HemoCell Specialized Lab Automation, with the largest installed base of Hemostasis automation workcells globally.
  • "This significant continuation of our long-term distribution agreement is a testament to the strength of our partnership with Thermo Fisher Scientific," said Remo Tazzi, Vice President, Worldwide Marketing and Service, Hemostasis and Acute Care Diagnostics at Werfen.
  • HemoHub™ Intelligent Data Manager centralizes management of Hemostasis testing  and intelligent sample routing with real-time adaptations and queue balancing.

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, May 4, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, HTRS, CHDI, Bachelor of Medicine, Bachelor of Surgery, Patisiran, PEG, Haemophilia, APOLLO, Acquisition, Patient, RNA interference, Cardiomyopathy, Brazilian Health Regulatory Agency, Polyneuropathy, The Lancet, Tissue, Therapy, NASH, Quarter, Corporate social responsibility, Brain, Medication, Randomness, Corporation, Liver, Growth, Innovation, Lancet, Viral hepatitis, Conference, Eos, Safety, ANVISA, Workplace, AHP, Hepatitis B virus, Truly Madly Deeply – Ultra Rare Tracks, Gene silencing, Shanda, Sanofi, HBV, Central nervous system, CER, Regeneron Pharmaceuticals, RTE, SAD, CNS, Peripheral nervous system, TTR, ATTR, Amyloidosis, Hemostasis, Pharmaceutical industry, Vaccine, Management, Cryptocurrency, Inclisiran, Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.
  • Attained over 3,160 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of March 31, 2023.
  • Alnylam announces today that it intends to present 18-month results from the APOLLO-B Phase 3 study of patisiran at ESC-HF 2023, being held May 20-23, 2023 in Prague.
  • Financial Results for the Quarter Ended March 31, 2023

Corza Medical Announces Direct Distribution of TachoSil® to the US Market

Retrieved on: 
Thursday, April 20, 2023
Surgeon, Atmosphere, TachoSil, Thrombin, Fibrinogen, Hemostasis, Patient, Fibrin, Baxter International, SVP, Pharmaceutical industry, Nursing, Takeda

WESTWOOD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) announced strategic plans to directly sell TachoSil®, a best-in-class surgical fibrin sealant patch trusted by medical professionals worldwide, to the U.S. market effective April 2023.

Key Points: 
  • WESTWOOD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) announced strategic plans to directly sell TachoSil®, a best-in-class surgical fibrin sealant patch trusted by medical professionals worldwide, to the U.S. market effective April 2023.
  • Corza Medical acquired TachoSil in January 2021 from Takeda, who previously had Baxter Healthcare distribute TachoSil exclusively in the U.S. market.
  • Corza Medical ended the agreement effective March 31, 2023.
  • “Distributing TachoSil directly to customers in the U.S. market demonstrates our commitment to advancing and growing this renowned product,” said Tom Testa Corza Medical CEO.